Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
A total of 89 patients with benign prostatic hyperplasia (BPH) were treated pharmacologically for 4 months: 51 received Cernilton and 38 Tadenan (controls). Significant subjective improvement was found in 78% of the patients in the Cernilton group compared to only 55% of the Tadenan-treated patients. The obstructive and irritative symptoms responded best to the therapy. In the Cernilton-treated patients a significant improvement in the uroflow rate, decrease in residual urine and in prostate volume were found. This study shows that Cernilton is an effective therapy for patients with BPH.
Dutkiewicz
S
S
Department of Urology, Central Clinical Hospital, Warsaw, Poland.
D000368:Aged; D005233:Fatty Alcohols / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D011467:Prostate / Q000000981:diagnostic imaging; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D012434:Secale; D014463:Ultrasonography; D014563:Urodynamics
D005233:Fatty Alcohols; D010936:Plant Extracts; C009375:Tadenan; C010070:cernilton